Latest Cann (ASX:CAN) News

Cann Group Limited has executed a transformative debt restructure, reducing its $70 million debt by 81% and raising $9 million in fresh capital, setting the stage for a positive EBITDA turnaround in FY26.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

Cann Group Limited has extended the expiry of its NAB debt facilities by two weeks, providing a brief but vital window to advance its refinancing plans.

Cann Group Limited has reported its first-ever EBITDA-positive month in August 2025, driven by strong B2B flower sales and disciplined cost management. The company is advancing export negotiations in Europe and preparing to launch a new Botanitech product range.

Cann Group Limited has disclosed a late payment of over $1.37 million in interest and facility fees to National Australia Bank, which has issued a non-waiver letter but is holding off on immediate action. The company is actively negotiating financing arrangements and plans to update the market by the end of September 2025.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.

Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

Cann Group Limited reported a 20% rise in Q3 production and improved operating cash flow, while navigating a 38% sales dip due to order timing. The company bolstered its balance sheet with new funding and expanded its Botanitech distribution network.